Kiora Q1 cash $13.9M, $5.0M equity raise post-quarter; KIO-301 enrollment nearly 50% in Phase 2

KIORA PHARMACEUTICALS INC

2026-Q1 EPS reported -$0.58

Q1 cash $13.9M; post-quarter raised $5.0M in equity from Perceptive Advisors; operational runway into late 2028.
Phase 2 ABACUS-2 enrollment for KIO-301 nearly 50% completed; trial sites expanding due to strong patient demand.
ABACUS-1 results published in Nature Medicine, validating KIO-301 photoswitch technology for vision restoration.
Phase 2 KLARITY study of KIO-104 progressing; safety review upcoming to enable dose escalation.
R&D expenses $2.1M with $1.2M Théa reimbursement; G&A $1.6M; collaboration receivables $1.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

KIORA PHARMACEUTICALS INC reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress.

View on SEC.gov

Browse all earnings releases →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-26-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.